These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28828689)

  • 1. Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
    Beck J; Schwarzer A; Gläser D; Mügge LO; Uhlig J; Heyn S; Kragl B; Mohren M; Hoffmann FA; Lange T; Schliwa T; Zehrfeld T; Becker C; Kreibich U; Winkelmann C; Edelmann T; Andrea M; Bill M; Jentzsch M; Schwind S; Niederwieser D; Pönisch W
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2545-2553. PubMed ID: 28828689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
    Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
    Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
    Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2
    Mey UJ; Brugger W; Schwarb H; Pederiva S; Schwarzer A; Dechow T; Jehner P; Rauh J; Taverna CJ; Schmid M; Schmidt-Hieber M; Doerfel S; Fischer N; Ruefer A; Ziske C; Knauf W; Cathomas R; von Moos R; Hitz F; Sauter R; Hiendlmeyer E; Cantoni N; Bargetzi M; Driessen C
    Br J Haematol; 2017 Mar; 176(5):770-782. PubMed ID: 27983764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
    Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
    Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
    Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
    Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
    Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
    Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
    Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
    Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
    Kumar S; Sharma A; Malik PS; Gogia A; Pathak N; Sahoo RK; Gupta R; Prasad CP; Kumar L
    Br J Haematol; 2022 Jul; 198(2):288-297. PubMed ID: 35499209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
    Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
    Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
    Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
    Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.